Chinese and foreign brands compete for Chinese 20 billion in vitro diagnostic market
Core tip: Through in vitro diagnostic (IVD) technology, the discovery time of cancer lesions can be greatly advanced. It is understood that the current public hospital laboratory IVD diagnosis accounted for nearly 90% of the market share. Including Roche, AstraZeneca, GE Medical and many other international pharmaceutical companies and medical device giants are speeding up the layout, with domestic brands to grab market share in vitro diagnostics. "In the United States, the five-year survival rate for cancer patients from 2003 to 2009 is about 68%, while in China the figure is only 25%. In addition to the gap in medical standards between China and the United States, the main reason for this is actually the time when cancer lesions are found. In the United States, many cancer patients are found in the early stage, and the success rate of cure is high through therapeutic intervention. However, most of the cancer patients in China are found in the middle and late stage, which brings difficulty to the treatment." A Shanghai hospital laboratory experts told reporters.
At present, this situation is facing improvement. Through in vitro diagnostic (IVD) technology, the time of discovery of cancer lesions can be greatly advanced. It is understood that the current public hospital laboratory IVD diagnosis accounted for nearly 90% of the market share. Including Roche, AstraZeneca, GE Medical and many other international pharmaceutical companies and medical device giants are speeding up the layout, with domestic brands to grab market share in vitro diagnostics.
What is in vitro diagnostics?
For example, in the past, when a suspected cancer patient found an abnormality in a certain part of the body through imaging equipment in the hospital, the doctor would often notify the patient to "follow-up" and continue to observe. If there is no development after a few months, it can be judged that "canceration" is unlikely. If the lesion continues to develop, it is judged that there is "canceration" or other possibilities and further examination is needed.
In such a screening process, not only the "golden March" of early treatment of cancer patients is easily delayed, but more often for patients with slow development of lesions, it is not easy to be detected in the early stage, thus missing the best time for treatment.
But if through IVD means, through the extraction of body tissue, secretions, blood and other samples, the lesion can be clearly detected in the early stage, greatly earlier diagnosis time.
This detection technology is widely used in China, especially in the top three hospitals in big cities. According to previous statistics, the per capita annual use of in vitro diagnostic products in China is only US $1.5, while the per capita annual use in developed countries has reached US $25-30, and the market prospect is huge.
"In the field of molecular diagnostic testing reagents, domestic brands are still the main ones, because the cost of a single test in hospitals is set by the State Food and Drug Administration to be relatively low, while most imported reagents are more expensive and there are not many types, so domestic brands are still more popular." Ni Weiqin, deputy general manager of Shanghai Zhijiang Biotechnology Co., Ltd., told reporters.
Take Zhijiang's HPV high-risk product for detecting cervical cancer as an example. Roche actually has the same product layout, but its market share is far lower than that of domestic brands.
"At present, our sales have reached hundreds of millions of levels every year, and we also have plans to go public. In the field of molecular diagnostic reagents, such as Daan Gene, domestic strength is not much worse than imports." Ni Weiqin added.
Although domestic brands are likely to catch up with each other in the field of testing reagents, China's IVD industry still relies on multinational giants in the upstream and instrument ends. Some people in the industry have disclosed to reporters that foreign manufacturers currently control more than 75% of the market share, and the remaining 25% of the market share, corresponding to about 6 billion yuan, is competed by nearly 300 domestic enterprises. The fierce market competition is evident.
"At present, the in vitro diagnostic market is mainly divided into four categories, biochemical reagents to domestic brands, immunodiagnosis is dominated by imported brands, domestic brands occupy a certain share, molecular diagnosis market imports, domestic brands mixed fish and dragons, POCT (instant testing) to import-based. At present, the largest market share is in the biochemical reagents and immunodiagnosis of these two pieces." Wang Haijiao, a partner in in vitro diagnostic investment, told reporters.
According to the report on China's in vitro diagnostic industry released by the Prospective Industry Research Institute, the IVD market size in China was close to 20 billion yuan in 2013, and the growth rate is expected to remain at 16% ~ 18%. Taking the median value of 17%, according to the median growth rate of 17%, the scale of China's IVD industry will be around 38.4 billion yuan by 2018.